Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort
Gespeichert in:
| Titel: | Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort |
|---|---|
| Autoren: | Ram Sundar, Lance Turtle, Rohan Shotton, Ruth Suckling, Umair T Khan, Christian Hesford, Christopher Valerio, Philip Walker, Vaishnav Potti-Dhananjaya, Rebecca Lee, Nagesh Kalakonda, Daniel H. Palmer, Richard J. Jackson, Andrew R. Pettitt, Carlo Palmieri, Avith Jathanna, Ann Tivey, Gillian Brearton, Anne C Armstrong, Shaun Rahman, Alexander J. Stockdale, Talvinder Bhogal, Amir Norouzi |
| Quelle: | Leukemia & lymphoma Bhogal, T, Khan, UT, Lee, R, Stockdale, A, Hesford, C, Potti-Dhananjaya, V, Jathanna, A, Rahman, S, Tivey, A, Shotton, R, Sundar, R, Valerio, C, Norouzi, A, Palmieri, C & Armstrong, A 2021, 'Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.', Leukemia & lymphoma, vol. 62, no. 7, pp. 1682-1691. https://doi.org/10.1080/10428194.2021.1876865 Leukemia & Lymphoma |
| Verlagsinformationen: | Informa UK Limited, 2021. |
| Publikationsjahr: | 2021 |
| Schlagwörter: | Cross Infection/epidemiology, 0301 basic medicine, Cancer Research, Cross Infection, Manchester Cancer Research Centre, United Kingdom/epidemiology, SARS-CoV-2, COVID-19, Hematology, ResearchInstitutes_Networks_Beacons/mcrc, name=Manchester Cancer Research Centre, United Kingdom, 3. Good health, 03 medical and health sciences, COVID-19 Testing, 0302 clinical medicine, Oncology, Hematologic Neoplasms/epidemiology, Risk Factors, Hematologic Neoplasms, Humans, Female, Pandemics, Retrospective Studies |
| Beschreibung: | The COVID-19 pandemic has been a disruptive event for cancer patients, especially those with haematological malignancies (HM). They may experience a more severe clinical course due to impaired immune responses. This multi-center retrospective UK audit identified cancer patients who had SARS-CoV-2 infection between 1 March and 10 June 2020 and collected data pertaining to cancer history, COVID-19 presentation and outcomes. In total, 179 patients were identified with a median age of 72 (IQR 61, 81) and follow-up of 44 days (IQR 42, 45). Forty-one percent were female and the overall mortality was 37%. Twenty-nine percent had HM and of these, those treated with chemotherapy in the preceding 28 days to COVID-19 diagnosis had worse outcome compared with solid malignancy (SM): 62% versus 19% died [HR 8.33 (95% CI, 2.56-25), p |
| Publikationsart: | Article |
| Dateibeschreibung: | application/pdf |
| Sprache: | English |
| ISSN: | 1029-2403 1042-8194 |
| DOI: | 10.1080/10428194.2021.1876865 |
| Zugangs-URL: | https://www.tandfonline.com/doi/pdf/10.1080/10428194.2021.1876865?needAccess=true https://pubmed.ncbi.nlm.nih.gov/33508995 https://research.manchester.ac.uk/en/publications/908ce5fa-366e-44d0-817d-271a1c4f8cfd https://doi.org/10.1080/10428194.2021.1876865 http://www.ncbi.nlm.nih.gov/pubmed/33508995 https://www.scilit.net/article/6e5ef994fbdd88a72db9190ef8c76e8f?action=show-references https://www.research.manchester.ac.uk/portal/en/publications/haematological-malignancy-and-nosocomial-transmission-are-associated-with-an-increased-risk-of-death-from-covid19-results-of-a-multicenter-uk-cohort(908ce5fa-366e-44d0-817d-271a1c4f8cfd).html https://search.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/ar/covidwho-1054169 https://www.tandfonline.com/doi/full/10.1080/10428194.2021.1876865 https://www.ncbi.nlm.nih.gov/pubmed/33508995 https://research.manchester.ac.uk/en/publications/908ce5fa-366e-44d0-817d-271a1c4f8cfd https://doi.org/10.1080/10428194.2021.1876865 http://europepmc.org/abstract/med/33508995 |
| Rights: | CC BY |
| Dokumentencode: | edsair.doi.dedup.....b7ace3ad486cdcf2b19e33e1e67b1f7f |
| Datenbank: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | The COVID-19 pandemic has been a disruptive event for cancer patients, especially those with haematological malignancies (HM). They may experience a more severe clinical course due to impaired immune responses. This multi-center retrospective UK audit identified cancer patients who had SARS-CoV-2 infection between 1 March and 10 June 2020 and collected data pertaining to cancer history, COVID-19 presentation and outcomes. In total, 179 patients were identified with a median age of 72 (IQR 61, 81) and follow-up of 44 days (IQR 42, 45). Forty-one percent were female and the overall mortality was 37%. Twenty-nine percent had HM and of these, those treated with chemotherapy in the preceding 28 days to COVID-19 diagnosis had worse outcome compared with solid malignancy (SM): 62% versus 19% died [HR 8.33 (95% CI, 2.56-25), p |
|---|---|
| ISSN: | 10292403 10428194 |
| DOI: | 10.1080/10428194.2021.1876865 |